KRAS and neoplasm: Additionally, oncogenic KRAS has been demonstrated to facilitate SUMOylation-dependent release of extracellular vesicles and promote lymphangiogenesis, hence enhancing the interplay between intracellular oncogenic signaling and the tumor microenvironment [255].